The Global Pipeline of New Medicines for the Control and Elimination of Malaria

Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg JMoehrle; Timothy NC Wells


Malar J. 2012;11(316) 

In This Article


The pipeline of new molecules targeting malaria is much richer now than it was two years ago.[167] Two significant events have occurred: first, new medicines have moved down the pipeline, specifically the prequalification of artesunate for severe malaria and the stringent regulatory approval of DHA-piperaquine and pyronaridine-artesunate as new fixed-dose anti-malarials. Second, and arguably more interesting, is the number of new molecules and new classes of molecules that are entering the pipeline. There are at least seven new compound families that have been discovered in the past five years. This is a rich portfolio and reflects the commitment of the field as a whole. Nonetheless, from a portfolio point of view there are still gaps. The chance that a new molecule entering Phase I studies will make it to registration is still around 20% for anti-infectives, and for a new combination two molecules would be needed. In addition, new TPPs have emerged from the malaria eradication agenda and compounds need to be measured against these, focusing on transmission-blocking and anti-relapse potential. With the sustained commitment of all of partners – donors, scientists, academics and the pharmaceutical industry – the next decade will be a very exciting time to be in clinical development of new therapeutics for malaria.